Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa

被引:18
作者
Gasink, Leanne B. [1 ]
Fishman, Neil O. [1 ]
Nachamkin, Irving [1 ]
Bilker, Warren B. [1 ]
Lautenbach, Ebbing [1 ]
机构
[1] Univ Penn, Ctr Biostat & Epidemiol, Sch Med, Dept Biostat & Epidemiol,Dept Pathol & Lab Med, Philadelphia, PA USA
关键词
D O I
10.1086/520740
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE. To identify risk factors for infection or colonization with aztreonam-resistant Pseudomonas aeruginosa and examine the impact of this organism on mortality. DESIGN. A case-control study was performed to identify risk factors for infection or colonization with aztreonam-resistant P. aeruginosa. A cohort study was subsequently performed to examine the impact of aztreonam resistance on outcomes. SETTING. A tertiary referral center in southeastern Pennsylvania. PARTICIPANTS. Inpatients with a clinical culture positive for P. aeruginosa between January 1, 1999, and December 31, 2000. RESULTS. Of 720 P. aeruginosa. isolates, 183 ( 25.4%) were aztreonam-resistant and 537 ( 74.6%) were aztreonam susceptible. In a multivariable model, prior fluoroquinolone use ( adjusted odds ratio [ aOR], 1.81 [ 95% confidence interval {CI}, 1.17-2.80]), prior use of an antianaerobic agent ( aOR, 1.56 [ 95% CI, 1.06-2.29]), and renal insufficiency ( aOR, 1.59 [ 95% CI, 1.10-2.29]) were associated with infection or colonization with aztreonam-resistant P. aeruginosa, while older age ( aOR, 0.98 [ 95% CI, 0.97-0.99] per year of age) was negatively associated with infection or colonization with this organism. In-hospital mortality was higher among subjects infected or colonized with aztreonam-resistant P. aeruginosa, compared with those who were infected or colonized with aztreonam-susceptible P. aeruginosa ( 25.7% vs 16.8%; P = .009), but in multivariable analysis, no significant association was found between infection or colonization with aztreonam-resistant P. aeruginosa and mortality. CONCLUSIONS. Curbing the use of fluoroquinolones and antimicrobials with antianaerobic activity may be an effective strategy to limit the emergence of aztreonam-resistant P. aeruginosa.
引用
收藏
页码:1175 / 1180
页数:6
相关论文
共 32 条
[1]   Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres:: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001) [J].
Andrade, SS ;
Jones, RN ;
Gales, AC ;
Sader, HS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :140-U7
[2]  
[Anonymous], AM J MED
[3]  
BARTON TD, 2005, INFECT CONT HOSP EP, V26, P69
[4]   Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections [J].
Cao, B ;
Wang, H ;
Sun, H ;
Zhu, Y ;
Chen, M .
JOURNAL OF HOSPITAL INFECTION, 2004, 57 (02) :112-118
[5]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[6]  
El Amari EB, 2001, CLIN INFECT DIS, V33, P1859, DOI 10.1086/324346
[7]   Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002 [J].
Flamm, RK ;
Weaver, MK ;
Thornsberry, C ;
Jones, ME ;
Karlowsky, JA ;
Sahm, DF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2431-2436
[8]   Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998 [J].
Fluit, AC ;
Jones, ME ;
Schmitz, FJ ;
Acar, J ;
Gupta, R ;
Verhoef, J .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) :454-460
[9]   Antimicrobial resistance in European isolates of Pseudomonas aeruginosa [J].
Fluit, AC ;
Verhoef, J ;
Schmitz, FJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (05) :370-374
[10]  
GASINK LB, 2006, 45 INT C ANT AG CHEM, P343